Veterinary mRNA Vaccines Market Share, Sales Volume, Price Analysis Report 2026
Global Info Research‘s report is a detailed and comprehensive analysis for global Veterinary mRNA Vaccines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the Veterinary mRNA Vaccines market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
According to our latest research, the global Veterinary mRNA Vaccines market size will reach USD 34870 million in 2031, growing at a CAGR of 40.1% over the analysis period.
Veterinary mRNA vaccines are a new generation of vaccines designed to protect animals from infectious diseases using messenger RNA (mRNA) technology. These vaccines work by delivering synthetic mRNA into animal cells, instructing them to produce specific antigens that trigger an immune response without using live pathogens. Compared to traditional vaccines, mRNA vaccines offer advantages such as faster development, adaptability to emerging diseases, and the ability to target multiple pathogens. They are being developed for livestock, poultry, and companion animals to combat diseases like avian influenza, swine fever, and canine influenza, improving animal health and food security.
Compared to traditional vaccines, mRNA vaccines have demonstrated revolutionary advantages in the field of animal health. This technology introduces mRNA sequences encoding specific antigens of pathogens into animal cells, directing the cells to synthesize antigen proteins and thus stimulating an immune response. This mechanism avoids the production complexities of traditional inactivated or live attenuated vaccines while possessing the ability to rapidly respond to emerging diseases. This technological characteristic is particularly important in the context of frequent outbreaks of major animal diseases such as African swine fever and avian influenza. The animal mRNA vaccine market is in the early stages of explosive growth, with the first peak in market launches expected between 2026 and 2028.
In terms of product type, animal mRNA vaccines mainly fall into two categories: non-replicating mRNA vaccines and self-replicating mRNA vaccines. Non-replicating mRNA vaccines have a simple structure, flexible sequence design, rapid antigen replacement (e.g., to address viral mutations), mature production processes (in vitro transcription + LNP encapsulation), no risk of genome integration, and no infectious particles; the toxicity of LNP delivery systems is controllable, and clinical adverse reactions are mainly mild to moderate (e.g., local pain, fever). Currently, most domestic companies pursue rapid market launch and development of multivalent vaccines, which are primarily non-replicating mRNA vaccines. In contrast, self-amplifying mRNA vaccines use replicase to amplify the mRNA copy number, and ng-level doses can induce a strong immune response (antibody titers increased more than 10-fold in animal experiments). Antigen expression lasts for several weeks, and a single dose can provide long-term protection.
This report is a detailed and comprehensive analysis for global Veterinary mRNA Vaccines market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Market segment by Type: Non-replicating mRNA Vaccine、 Self-amplifying mRNA Vaccine
Market segment by Application:Pigs、 Poultry、 Ruminants、 Companion Animals
Major players covered: Merck Animal Health、 Ceva Animal Health、 Tiba Biotechnology、 Jinyu Biotechnology、 Harbin Enwei Biological Pharmaceutical、 Shanghai Rnacure Biopharma、 Ruipu Biotechnology、 Jiangsu Synthgene Biotechnology、 Genvax Technologies、 Shanghai Shen Lian Biomedical、 Suzhou Kerui Meide Biomedical Technology
According to our latest research, the global Veterinary mRNA Vaccines market size will reach USD 34870 million in 2031, growing at a CAGR of 40.1% over the analysis period.
Veterinary mRNA vaccines are a new generation of vaccines designed to protect animals from infectious diseases using messenger RNA (mRNA) technology. These vaccines work by delivering synthetic mRNA into animal cells, instructing them to produce specific antigens that trigger an immune response without using live pathogens. Compared to traditional vaccines, mRNA vaccines offer advantages such as faster development, adaptability to emerging diseases, and the ability to target multiple pathogens. They are being developed for livestock, poultry, and companion animals to combat diseases like avian influenza, swine fever, and canine influenza, improving animal health and food security.
Compared to traditional vaccines, mRNA vaccines have demonstrated revolutionary advantages in the field of animal health. This technology introduces mRNA sequences encoding specific antigens of pathogens into animal cells, directing the cells to synthesize antigen proteins and thus stimulating an immune response. This mechanism avoids the production complexities of traditional inactivated or live attenuated vaccines while possessing the ability to rapidly respond to emerging diseases. This technological characteristic is particularly important in the context of frequent outbreaks of major animal diseases such as African swine fever and avian influenza. The animal mRNA vaccine market is in the early stages of explosive growth, with the first peak in market launches expected between 2026 and 2028.
In terms of product type, animal mRNA vaccines mainly fall into two categories: non-replicating mRNA vaccines and self-replicating mRNA vaccines. Non-replicating mRNA vaccines have a simple structure, flexible sequence design, rapid antigen replacement (e.g., to address viral mutations), mature production processes (in vitro transcription + LNP encapsulation), no risk of genome integration, and no infectious particles; the toxicity of LNP delivery systems is controllable, and clinical adverse reactions are mainly mild to moderate (e.g., local pain, fever). Currently, most domestic companies pursue rapid market launch and development of multivalent vaccines, which are primarily non-replicating mRNA vaccines. In contrast, self-amplifying mRNA vaccines use replicase to amplify the mRNA copy number, and ng-level doses can induce a strong immune response (antibody titers increased more than 10-fold in animal experiments). Antigen expression lasts for several weeks, and a single dose can provide long-term protection.
This report is a detailed and comprehensive analysis for global Veterinary mRNA Vaccines market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Market segment by Type: Non-replicating mRNA Vaccine、 Self-amplifying mRNA Vaccine
Market segment by Application:Pigs、 Poultry、 Ruminants、 Companion Animals
Major players covered: Merck Animal Health、 Ceva Animal Health、 Tiba Biotechnology、 Jinyu Biotechnology、 Harbin Enwei Biological Pharmaceutical、 Shanghai Rnacure Biopharma、 Ruipu Biotechnology、 Jiangsu Synthgene Biotechnology、 Genvax Technologies、 Shanghai Shen Lian Biomedical、 Suzhou Kerui Meide Biomedical Technology
To Get More Details About This Study, Please Click Here: https://www.globalinforesearch.com/reports/3219731/veterinary-mrna-vaccines
The overall report focuses on primary sections such as – market segments, market outlook, competitive landscape, and company profiles. The segments provide details in terms of various perspectives such as end-use industry, product or service type, and any other relevant segmentation as per the market’s current scenario which includes various aspects to perform further marketing activity. The market outlook section gives a detailed analysis of market evolution, growth drivers, restraints, opportunities, and challenges, Porter’s 5 Force’s Framework, macroeconomic analysis, value chain analysis and pricing analysis that directly shape the market at present and over the forecasted period. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also gives an indication of the trends influencing new business development and investment opportunities.
The Primary Objectives in This Report determine the size of the total market opportunity of global and key countries,assess the growth potential for Veterinary mRNA Vaccines and competitive factors affecting the marketplace,forecast future growth in each product and end-use market. Also,this report profiles key players in the global Veterinary mRNA Vaccines market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments.
Veterinary mRNA Vaccines market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by region, regional analysis covers North America (United States, Canada, and Mexico),Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe),Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia),South America (Brazil, Argentina, Colombia, and Rest of South America),Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa).
The report provides insights regarding the lucrative opportunities in the Veterinary mRNA Vaccines Market at the country level. The report also includes a precise cost, segments, trends, region, and commercial development of the major key players globally for the projected period.
The Veterinary mRNA Vaccines Market report comprehensively examines market structure and competitive dynamics. Researching the Veterinary mRNA Vaccines market entails a structured approach beginning with clearly defined objectives and a comprehensive literature review to understand the current landscape. Methodologies involve a mix of primary research through interviews, surveys, and secondary research from industry reports and databases. Sampling strategies ensure representation, while data analysis utilizes statistical and analytical techniques to identify trends, market sizing, and competitive landscapes. Key areas of focus include trend analysis, risk assessment, and forecasting. Findings are synthesized into a detailed report, validated through peer review or expert consultation, and disseminated to stakeholders, with ongoing monitoring to stay abreast of developments.
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
